The $400 million cash purchase boosts Abbott’s presence in the vision-care segment, which it entered in February with the acquisition of Advanced Medical Optics, according to a prepared statement from the company. “Visiogen immediately provides Abbott Medical Optics [AMO] with a talented team of dedicated professionals and an entry point into the accommodating IOL market,” said Jim Mazzo, senior vice president, AMO. The proprietary accommodating IOL received CE mark designation and has been available commercially in Europe since January. It is under review by the FDA. |
Featured JobsCoding Counselor Simple and accurate ICD-9 code search. Start Here Patient Education Print customized patient education handouts. Start Here Dermatology Diagnosis Identify skin diseases by age, gender, location. Start Here AHRQ Clinical Guidelines Objective findings on medical interventions. Start Here ![]() ![]() |